Patients Recruitment to Start by November 1
HALIFAX, Sept. 28, 2012 /CNW/ - The Honourable Leona Aglukkaq, Minister
of Health, today announced that a national MS clinical trial has
received the necessary medical and ethical approvals required to
proceed. The clinical trial is a collaborative initiative between the
Government of Canada, the provinces and territories and the MS Society
Dr. Anthony Traboulsee, Medical Director of the UBC Hospital MS Clinic,
and his collaborators received ethics approvals from institutions in
British Columbia and Québec to undertake a clinical trial for Chronic
Cerebrospinal Venous Insufficiency (CCSVI) in persons with multiple
The recruitment of patients will begin by November 1, 2012.
Approximately 100 patients are expected to participate in the trial, to
be conducted in British Columbia and Québec. Ethics approval is also
being sought in Manitoba. Funding of the $6 million study is a
collaborative effort of the Canadian Institutes of Health Research
(CIHR), the MS Society of Canada and the provinces where the trial will
"I'm pleased to congratulate the team of researchers who will be
studying the safety and effectiveness of the CCSVI procedure," said
Minister Aglukkaq. "Our government is committed to working with the
provinces and territories to advance research in MS with the goal of
improving the health of Canadians who live with this debilitating
"The support that the Government of Canada and the MS Society of Canada
has received from provincial and territorial partners is instrumental
in the rollout of the clinical trial that will help ensure a shared
national understanding of the procedure proposed by Dr. Paolo Zamboni,"
said Dr. Alain Beaudet, President of CIHR.
"As we move through this important new phase of MS research, we look
forward to Dr. Traboulsee and his team furthering the work of the
Canadian research community and providing more insights about CCSVI for
those living with MS," said Yves Savoie, President and CEO of the MS
Society of Canada.
"This pan Canadian controlled study will allow us to monitor MS patients
over a two-year period and obtain scientific evidence on the safety and
efficacy of the CCSVI procedure in the long term," said Dr. Traboulsee,
Medical Director of the UBC Hospital MS Clinic, President of the
Canadian Network of MS Clinics, and Assistant Professor in the UBC
Faculty of Medicine.
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency.
CIHR's mission is to create new scientific knowledge and to enable its
translation into improved health, more effective health services and
products, and a strengthened Canadian health care system. Composed of
13 Institutes, CIHR provides leadership and support to more than 14,100
health researchers and trainees across Canada.
The UBC Hospital MS Clinic is a world leader for innovative research using MRI to study and
evaluate Multiple Sclerosis treatments as well as genetic epidemiology.
It is led by a world renowned MS clinical research team comprised of
specialists in pharmaceutical and interventional therapies, imaging,
and genetics from Vancouver Coastal Health and UBC. The clinic, which
cares for 80 - 90 percent of MS patients in British Columbia is home to
the world's largest MS database of over 7500 patients, many of whom
have been followed for over 25 years. The UBC Hospital MS Clinic is a
member of the Canadian Network of MS Clinics, a national network of
academic and community based clinics established for the advancement of
patient services, education, and research in Multiple Sclerosis.
SOURCE: Canadian Institutes of Health Research
For further information:
CIHR Media Relations, 613-941-4563, email@example.com
Ce document est également disponible en français.